TRAW · Nasdaq · ·
$0.62+8.6%Sep 29 close
The quarter ending December 31, 2025, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2025 | 3 months toDec 31, 2024 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $56K | -100.00% |
| Profit | -$3.1M | -$915K | -233.77% |
| Profit per share | -$0.16 | -$0.11 | -45.45% |
| Free Cash Flow | -$2.8M | -$5.5M | +49.56% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Traws Pharma, Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Tivoxavir marboxil (TXM) is an investigational oral, small molecule CAP-dependent endonuclease inhibitor designed to be administered as a single-dose prophylactic agent for seasonal influenza and treatment of pandemic/bird flu. It has shown potent in vitro activity against a range of influenza strains in preclinical studies, including a human isolate of the highly pathogenic avian flu H5N1 (bird flu). Consistent, positive preclinical data from three animal species indicate that a single dose of TXM demonstrated a therapeutic effect against H5N1 bird flu. Seasonal influenza represents an estimated multi-billion-dollar antiviral market opportunity, largely driven by global health organizations, practice guidelines and government tenders and inclusion in drug stock piling initiatives 1,2 , with upside potential from potential pandemic flu outbreaks including H5N1 bird flu. Source information 1. Per link 2. Traws data on file Third-party products mentioned herein are the trademarks of their respective owners.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Traws Pharma, Inc.’s Item 2.02 8-K filed August 14, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.